These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17012606)

  • 1. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Dexter DT; Croucher MJ
    J Pharmacol Exp Ther; 2007 Jan; 320(1):397-409. PubMed ID: 17012606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
    Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
    Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.
    Gasparini F; Bruno V; Battaglia G; Lukic S; Leonhardt T; Inderbitzin W; Laurie D; Sommer B; Varney MA; Hess SD; Johnson EC; Kuhn R; Urwyler S; Sauer D; Portet C; Schmutz M; Nicoletti F; Flor PJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1678-87. PubMed ID: 10336568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
    Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
    Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake.
    Zhou F; Yao HH; Wu JY; Yang YJ; Ding JH; Zhang J; Hu G
    J Neurosci Res; 2006 Aug; 84(2):268-77. PubMed ID: 16752416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration.
    Maciejak P; Szyndler J; Turzyńska D; Sobolewska A; Taracha E; Skórzewska A; Lehner M; Bidziński A; Hamed A; Wisłowska-Stanek A; Płaźnik A
    Brain Res; 2009 Jul; 1282():20-7. PubMed ID: 19481536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
    Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
    Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
    J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
    Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
    Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
    Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
    Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
    Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
    Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.
    Betts MJ; O'Neill MJ; Duty S
    Br J Pharmacol; 2012 Aug; 166(8):2317-30. PubMed ID: 22404342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata.
    Wittmann M; Marino MJ; Conn PJ
    J Pharmacol Exp Ther; 2002 Aug; 302(2):433-41. PubMed ID: 12130700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabotropic glutamate system promotes neuronal survival through distinct pathways of programmed cell death.
    Vincent AM; Maiese K
    Exp Neurol; 2000 Nov; 166(1):65-82. PubMed ID: 11031084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article.
    Gołembiowska K; Konieczny J; Ossowska K; Wolfarth S
    Amino Acids; 2002; 23(1-3):199-205. PubMed ID: 12373538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
    Vernon AC; Croucher MJ; Dexter DT
    Neuroreport; 2008 Mar; 19(4):475-8. PubMed ID: 18287950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.